-
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint
NASDAQ: $ABOS NEWTON, Mass., Oct. 30, 2026 October 30, 2026 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target… Source: Read More
-
A Breakthrough in Alzheimer’s Treatment: Solengepras Shows Promise in Phase 3 Trials
New Hope for Alzheimer’s Patients Cerevance recently announced promising results from its Phase 3 ARISE clinical trial, marking a potential turning point in the treatment of Alzheimer’s disease. The study evaluated the efficacy and safety of solengepras, a novel once-daily oral medication designed to address the progression of cognitive decline. Meeting Primary Endpoints The ARISE…
-
Presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial highlighting new findings from the ATTENTION-AD study evaluating potential benefit of oral once daily blarcamesine (ANAVEX®2-73) in early Alzheimer’s disease.
NASDAQ: $AVXL The presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial marks a significant milestone in the field of Alzheimer’s disease research. This article delves into the latest findings from the ATTENTION-AD trial, shedding light on the efficacy and safety of the investigational treatment over an extended period. With a…
-
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer’s
NASDAQ: $SNPX 1. Introduction: Synaptogenix’s participation in USC-Sponsored Forum on Age-Related Diseases Synaptogenix, a renowned leader in the field of neurology and Alzheimer’s research, is set to join a distinguished group of neuroscientists and academics as a speaker at the USC-Sponsored Forum on Age-Related Diseases. This eagerly anticipated event aims to delve into the latest…